

**NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART,  
DIRECTLY OR INDIRECTLY, TO UNITED STATES NEWS WIRE SERVICES OR IN OR  
INTO, AUSTRALIA, CANADA, JAPAN, THE UNITED STATES OF AMERICA OR SOUTH  
AFRICA OR ANY JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS  
ANNOUNCEMENT.**



**For Immediate Release**

**29 March 2016**

**Levrett Plc**  
("Levrett" or "the Company")

**Interim Results**  
for the period ended 31 December 2015

Levrett, a Company formed to acquire a target company with realisable or developed commercial technologies in the pharmaceutical and biotechnology sector, announces its interim results for the period ended 31 December 2015.

**Enquiries:**

**Levrett Plc** +44 (0) 20 7183 4342  
Pascal Hughes, CEO

**EGR Broking Limited** +44 (0)203 697 9496  
Leo Godsall / Jonathan Hall

**Whitman Howard Limited** +44 (0) 20 7659 1234  
Niall Baird / Nick Lovering

**Gable Communications Limited** +44 (0) 20 7193 7463  
John Bick +44 (0) 7872 061007  
e: [levrett@gablecommunications.com](mailto:levrett@gablecommunications.com)

# LEVRETT PLC

## CHAIRMAN'S STATEMENT FOR THE PERIOD ENDED 31 DECEMBER 2015

---

### Introduction

These are the results for Levrett Plc for the interim period ended 31 December 2015.

The company was incorporated on 10 June 2015 and was admitted to the Official List of the UK Listing Authority on 17 December 2015.

### Financial review

In the period to 31 December 2015, the Company recorded a loss of £197,929 (a loss per share of 0.37 pence). This includes certain non-recurring fees from the admission of shares to trading on the Standard List of the Main Market of the London Stock Exchange. The Company continues to be run with a measured and strategic approach to focus expenditure on identifying acquisition targets and performing necessary due diligence. The board does not recommend the payment of a dividend at this time.

### Outlook

The recent announcements with regards to Immuno-Oncology advances highlights one example of how the Biotechnology sector in the UK continues to evolve and develop. There are a number of significant opportunities that would make suitable investment targets for Levrett, which was formed to acquire a target company with realisable or developed commercial technologies in the pharmaceutical and biotechnology sector.

The Company has made considerable progress towards identifying such targets focussed on four specific strategic sectors, being; Oncology, Diabetes, Obesity and Mental Health. The Board has reviewed a number of specific targets to date, within the UK, Europe and the United States. Whilst some of these have not met the investment criteria for the Company, the Board continues to review the other opportunities with a view to completing a suitable acquisition.

F J Lidgery

Chairman

29 March 2016

# LEVRETT PLC

## INTERIM STATEMENT OF COMPREHENSIVE INCOME FOR THE PERIOD ENDED 31 DECEMBER 2015

---

	<b>Unaudited period ended 31 December 2015 £</b>
Revenue	-
Administrative expenses	<u>(197,929)</u>
LOSS BEFORE TAX	(197,929)
Tax	-
LOSS FOR THE PERIOD	<u>(197,929)</u>
Other comprehensive income/(expense)	-
TOTAL COMPREHENSIVE EXPENSE FOR THE PERIOD	<u><u>(197,929)</u></u>

Loss before tax and total comprehensive expense for the period are all attributable to the equity shareholders of the company.

### Loss per share

Basic and diluted	<u>(0.37)p</u>
-------------------	----------------

# LEVRETT PLC

## INTERIM STATEMENT OF FINANCIAL POSITION FOR THE PERIOD ENDED 31 DECEMBER 2015

---

	Notes	Unaudited 31 December 2015 £
<b>ASSETS</b>		
<b>Current assets</b>		
Trade and other receivables		39,691
Cash and cash equivalents		684,901
		<hr/>
		724,592
		<hr/>
<b>TOTAL ASSETS</b>		<b>724,592</b>
		<hr/> <hr/>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Share capital	3	95,750
Share premium account		757,010
Retained earnings		(197,929)
		<hr/>
<b>Total equity attributable to equity holders of the parent</b>		<b>654,831</b>
		<hr/>
<b>Current liabilities</b>		
Trade and other payables		69,761
		<hr/>
<b>TOTAL LIABILITIES</b>		<b>69,761</b>
		<hr/>
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>724,592</b>
		<hr/> <hr/>

# LEVRETT PLC

## INTERIM STATEMENT OF CHANGES IN EQUITY FOR THE PERIOD ENDED 31 DECEMBER 2015

---

	Share capital	Share Premium account	Retained earnings	Total
	£	£	£	£
<b>On Incorporation</b>	-	-	-	-
Total comprehensive expense for the period	-	-	(197,929)	(197,929)
Shares issued in the period	95,750	757,010	-	852,760
<b>Unaudited at 31 December 2015</b>	<u>95,750</u>	<u>757,010</u>	<u>(197,929)</u>	<u>654,831</u>

All equity is attributable to equity shareholders of the company.

### Share premium

Represents amounts subscribed for share capital in excess of its nominal value, net of directly attributable issue costs.

# LEVRETT PLC

## INTERIM STATEMENT OF CASH FLOWS FOR THE PERIOD ENDED 31 DECEMBER 2015

---

	<b>Unaudited period ended 31 December 2015 £</b>
<b>Operating activities</b>	
Loss before tax	(197,929)
<b>Changes in working capital:</b>	
Increase in trade and other receivables	(39,691)
Increase in trade and other payables	69,761
<b>Net cash used in operating activities</b>	<hr/> (167,859)
<b>Financing activities</b>	
Share issue (net of costs)	852,760
<b>Net cash generated from financing activities</b>	<hr/> 852,760
<b>Taxation</b>	-
<b>Net increase in cash and cash equivalents</b>	684,901
Cash and cash equivalents at the start of the period	<hr/> -
Cash and cash equivalents at the end of the period	<hr/> <hr/> <hr/> 684,901

# LEVRETT PLC

## NOTES TO THE INTERIM FINANCIAL INFORMATION FOR THE PERIOD ENDED 31 DECEMBER 2015

---

### 1 General information

Levrett Plc is a publicly listed company incorporated and domiciled in England. The address of its registered office is Suite 31, 2<sup>nd</sup> Floor, 107 Cheapside, London. EC2V 6DN.

The Company is listed on the Official List.

This interim financial information was approved for issue on 29 March 2016.

### 2 Accounting policies

#### 2.1 Basis of preparation

The interim financial information comprises the Statements of Financial Position at 31 December 2015, the Statements of Comprehensive Income, Changes in Equity and Cash Flows for the period ended 31 December 2015 and the related notes of Levrett Plc, (hereinafter referred to as 'the interim financial information').

The interim financial information has been prepared in accordance with IAS 34, 'Interim Financial Reporting' as adopted by the European Union. In preparing this information, management have used the accounting policies set by the Company.

This interim financial information does not constitute a set of statutory accounts under the requirements of the Companies Act 2006 and is neither audited nor reviewed.

This document (the Interim Statement 2015) will be published on the company's website and will be publicly available from the London Stock Exchange regulatory publications. The maintenance and integrity of the Levrett Plc website is the responsibility of the directors. Legislation in the UK governing the preparation and dissemination of accounts may differ from legislation in other jurisdictions.

#### 2.2 Going concern

These financial statements have been prepared on the going concern basis based on the current cash flow projections for the following twelve months.

# LEVRETT PLC

## NOTES TO THE INTERIM FINANCIAL INFORMATION FOR THE PERIOD ENDED 31 DECEMBER 2015

---

<b>3</b>	<b>Share capital</b>	<b>Unaudited period ended 31 December 2015 £</b>
	<b>Issued and fully paid</b>	
	95,750,000 Ordinary shares issued of £0.001 each	<u>95,750</u>
		<u>95,750</u>

On Admission to the Official List, 45,750,000 of the above issued share capital was placed at a price of £0.02 per share with the premium (net of the issue costs) being shown in the share premium account.

On 7 December 2015, the company issued 50,000,000 founder warrants to the founder shareholders which entitles each warrant holder to subscribe for one ordinary share at 4 pence per share, exercisable any time.

On the same date, the company issued 957,500 warrants to EGR Broking Limited which entitles each warrant holder to subscribe for one ordinary share at 2 pence per share, exercisable any time.

### **4 Dividends paid and proposed**

#### **Equity dividends on ordinary shares:**

No interim dividend was paid or is proposed for the period ended 31 December 2015.

### **5 Loss per share**

The calculations of loss per share are based on the following results and number of shares:

	<b>Unaudited period ended 31 December 2015 £</b>
Loss for the financial period	<u>(197,929)</u>
Weighted average number of shares for diluted loss per share	<u>53,124,390</u>

At 31 December 2015, the number of ordinary shares in issue was 95,750,000.